These Biopharma Names Don’t Have the Flash of SpaceX, but They’re Reliable
Here are four biotech plays that should stand up if the market starts to break down.
While Everyone Was Selling, I Initiated a New Position in This Mid-Cap Biotech
I made exactly one trade Friday — and I went to Denmark to do it.